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ABSTRACT 
 
AIMS Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse 
outcomes in patients with heart failure (HF) has been described. However, response of TMAO 
levels to treatment and medications has not been investigated. Therefore, we investigated whether 
TMAO levels are responsive to guideline-recommended treatment and medications, and further 
reflect changes in outcomes. 
METHODS AND RESULTS TMAO levels were investigated in the systems BIOlogy Study to 
TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to 
guideline-recommended pharmacological treatment. TMAO levels in 2,234 patients with new-
onset or progressively worsening HF showed strong associations with adverse events (mortality 
and /or rehospitalisation) at 1,2 and 3 years (HR 1.37–1.51, p≤0.019). Analysis of 972 patients 
with plasma available at both enrolment and follow-up visit showed reductions of B-type 
natriuretic peptide levels with guideline-based treatment (p<0.001), but not for TMAO levels. 
Moreover, patients with higher TMAO levels than median before and after treatment showed 
increased association with adverse outcomes (HR 2.21, 95% CI: 1.43-3.43, p<0.001) compared to 
patients with lower than median levels either before or after treatment (HR 1.13, 95% CI: 0.63-
2.04, p=0.684 and HR 1.14, 95% CI: 0.64-2.03, p=0.662, respectively).  
CONCLUSION TMAO levels were associated with adverse outcomes (mortality and/or 
rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmaceutical 
treatment in contrast to BNP levels which did as expected. Lower TMAO levels regardless of 
treatment were associated with favorable outcome.  
 
Key Words: Heart failure, gut microbiome, biomarker, metabolite, outcome study  
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INTRODUCTION 
  
The pathophysiology underlying heart failure (HF) is complex with multifaceted 
contributions of mechanical and neurohormonal factors and their collective effects on the heart.1 
Recently, the contribution of the gut microbiome to heart failure has been a topic of interest with 
the identification of the phosphatidylcholine metabolite, trimethylamine N-oxide (TMAO), to be a 
gut microbiota-derived molecule whose circulating levels when elevated are strongly associated 
with adverse outcomes for both acute2 and chronic HF3-7 as determined by cross-sectional studies.  
TMAO production involves gut microbiome-mediated processing of carnitine and/or choline (e.g. 
red meat and egg yolk as dietary sources) to the precursor trimethylamine (TMA) which is then 
converted to TMAO by flavin-containing monooxygenase 3 (FMO3) in the liver.8,9 TMAO cannot 
be produced effectively if the gut microbiome is absent (e.g. antibiotics) or the diet is 
vegan/vegetarian-based.10 Whether TMAO levels are responsive to medication and treatment, and 
further reflects changes in outcomes remains unknown. We hypothesized that TMAO levels would 
not respond to guideline directed medical therapy as conventional medications for HF do not target 
the gut microbiome.  
 The systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-
CHF) was a European multicentre, prospective, observational project involving 69 centres in 11 
countries11, designed to implement current European guidelines of HF treatment12 and to 
characterise biological pathways related to drug responsiveness to guideline-recommended 
pharmacological treatment for HF. 
 The present study investigated the association of circulating TMAO levels to outcomes in 
this contemporary European HF cohort with a particular focus on association of serial TMAO 
levels with treatment and outcomes.   
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METHODS 
 
Study Population 
BIOSTAT-CHF has been described in full elsewhere.11 In brief, the BIOSTAT-CHF cohort 
enrolled 2516 patients in total between 2010-2014 with progressive worsening or new-onset 
symptoms of HF, confirmed by either a left ventricular ejection fraction (EF) of ≤40% or plasma 
concentrations of B-type natriuretic peptide (BNP) and/or N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) >400pg/ml or >2000pg/ml, respectively. The main aim of the project was to 
establish the effects of and response to initiation and up-titration of guideline-directed medical 
therapy, therefore all patients underwent treatment with furosemide ≥40mg/day or equivalent and 
received ≤50% of target doses of angiotensin-converting-enzyme inhibitors or angiotensin II 
receptors (ACEi/ARBs) and beta-blockers at time of study entry. Each patient consented (written 
and informed) to have blood samples taken and outcomes surveyed. The study complied with the 
Declaration of Helsinki and was approved by the local ethics committee. 
 
Sample Collection 
Blood samples were collected at the initial enrolment visit (V1) in all patients and at a 
follow-up visit (V2) at approximately nine months in possible patients.  
 
Biomarker Measurements 
Plasma was aliquoted and stored at -80 ºC until analysis. At the time of analysis, samples 
were defrosted at room temperature and analysed immediately. TMAO levels were measured in 
plasma samples using stable isotope dilution [d9-(trimethyl)-labelled TMAO] followed by ultra-
performance liquid chromatography-tandem mass spectrometry on a Quattro Premier XE triple 
quadrupole mass spectrometer (Waters Corp., Milford, MA, USA), using conditions described 
previously with a coefficient of variation of 5.7% for measurements throughout the study. 2,13 All 
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further clinical biomarkers were measured either at local hospital site or within the BIOSTAT-
CHF central laboratory.11 BNP was measured using Luminex multiplexed bead-based 
immunoassays at Alere (San Diego, California).   
 
Endpoints 
The primary outcome was all-cause mortality (mortality), with a secondary outcome 
measure as the composite event of mortality combined with rehospitalisation due to HF 
(mortality/HF). End points were obtained as previously reported for the BIOSTAT-CHF 
protocol.11 
 
Statistical Analyses 
Investigations were performed on a non-imputed BIOSTAT-CHF database and 
modifications were made where sufficient data were not available. For patients that completed a 
second visit, changes in demographics from initial enrolment visit (V1) to the follow-up visit (V2) 
were compared using Wilcoxon matched-pair signed-rank test for continuous variables and the 
McNemar test for categorical variables. Cumulative incidences of events were investigated using 
Kaplan-Meier survival curves for tertiles of TMAO at baseline and compared using the Mantel-
Cox log rank test. Cox proportional hazards regression analyses were performed to investigate 
association of plasma TMAO levels with outcomes in both a univariable and multivariable 
manner. 
 Multivariable adjustments were made using the previously defined BIOSTAT-CHF 
compact and extended risk models.14  
To investigate the implications of serial changes in plasma TMAO levels with treatment on 
outcomes, patients with data available for both V1 and V2 were further classified according to 
respective TMAO levels at each time point. In total, four groups were created and classified by 
low or high TMAO levels (according to the median) for each visit. Cox proportional hazards 
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regression analysis was performed to investigate the change in associations with outcomes across 
groupings, with low V1 and low V2 (L/L group) deemed as the reference value. Similar analysis 
was done with natriuretic peptide levels. Decision tree analysis was performed using χ2 automatic 
interaction detection (CHAID) and resultant groupings tested for association with outcomes using 
Cox proportional hazards regression and Kaplan-Meier survival curves. 
Statistical analyses were performed using IBM SPSS Statistics (v24, IBM, Armonk, NY, 
USA). A P-value of <0.05 was considered statistically significant.  
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RESULTS 
 
Study Population 
Plasma TMAO levels were determined in 2234 patients (88.8%) with available baseline 
plasma samples of the 2516 patients that were included in BIOSTAT-CHF. 
Patient demographics are shown in Table 1. The cohort consisted of 2234 patients with an 
age of 70 [61–78] years (median [interquartile range]) with 74% being male and 32% with history 
of previous HF hospitalisation. Patients were predominantly New York Heart Association 
(NYHA) functional classification of HF classes II and III (combined 86%), and presented with HF 
with reduced ejection fraction (EF) in 81%.  
Patient characteristics according to TMAO median and tertiles are shown in 
Supplementary Table S1. Patients with higher TMAO levels at baseline had more comorbidities, 
advanced heart failure and worsened renal function as well as less use of ACEi/ARB and 
mineralocorticoid receptor antagonist (MRA). 
972 out of the 2234 patients were analysed at follow up for TMAO levels (320 patients 
died before 9 months follow-up resulting in 1914 patients remaining of whom samples were 
available in 972 patients).  
This subset of 972 patients had undergone guideline-based treatment for HF and showed 
improvement in clinical variables (Table 1) as shown by reduction of congestion and peripheral 
oedema (-38% and -27%, p<0.001), reduction in BNP levels (from 206 [86-408] pg/mL to 132 
[51-327] pg/mL, p<0.001), reduction in NYHA class (e.g. 48% to 24% for NYHA class III) and 
improvement of EF (30% [25-35] to 35% [28-42], p<0.001). Use of beta-blocker, ACEi/ARBs and 
MRA were increased (85% to 93%, 74% to 89%, and 52% to 59% respectively, all p<0.001), and 
use of diuretics was reduced (100% to 94%, p<0.001) between V1 and V2.  
Differences in characteristics between patients with and without TMAO measurements at 
V1 and V2 are shown in Supplementary Table S2. More males were in the group with TMAO 
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measured as compared to those not measured at V1, and those not measured at V2 showed lower 
use of beta-blockers and ACEi/ARBs, and lower eGFR levels. 
 
Association of Circulating TMAO Levels with Adverse Outcomes 
During the 3-year observation period, there were 591 mortality events (26.5%) and 909 
composite events of mortality/HF (40.7%).  To understand the association of baseline plasma 
TMAO levels and outcomes, Kaplan-Meier survival analyses were performed across TMAO 
tertiles (tertile1=<4.2 µmol/L; tertile2=4.2-8.4 µmol/L; tertile3=>8.4 µmol/L). Patients with 
elevated TMAO levels were associated with more deaths and composite events during the 
observation period, with a graded increase in the cumulative incidence of events with increasing 
TMAO levels (p<0.001, Figure 1).  
To investigate the association of TMAO levels with outcomes, log TMAO levels were 
added to the previously described BIOSTAT-CHF compact and extended risk models for mortality 
and mortality/HF at 1, 2 and 3 years (11) (Table 2). The BIOSTAT-CHF compact risk model for 
mortality included age, haemoglobin, blood urea, log BNP and use of beta-blocker at baseline. 
BNP levels were substituted for NT-proBNP due to insufficient availability of data (data available 
in only 47% patients for NT-proBNP). When adjusted for this model, TMAO levels were 
associated with mortality and mortality/HF at 1, 2 and 3 years (HR 1.37-1.51, p≤0.019). The 
BIOSTAT-CHF extended risk model for mortality included ischaemic aetiology, previous chronic 
obstructive pulmonary disease, diastolic blood pressure (BP) and sodium in addition to variables 
previously described for the compact model of mortality. When adjustment using this model was 
performed, TMAO remained an independent predictor of outcome for mortality at all time points 
(HR 1.40-1.44, p≤0.030) (see Table 2 for detailed statistical results). The BIOSTAT-CHF 
compact risk model for mortality/HF included age, previous HF hospitalisation, peripheral 
oedema, systolic blood pressure, log BNP, haemoglobin, sodium and use of beta-blocker at 
baseline. High-density lipoprotein data were excluded due to availability in only 1036 patients 
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(46%). TMAO levels were associated with mortality/HF at all time points (p≤0.019). Finally, the 
BIOSTAT-CHF extended risk model for mortality/HF included current smoking, previous chronic 
obstructive pulmonary disease and estimated glomerular filtration rate (eGFR) in addition to the 
variables of the compact model. Presence of raised jugular vein dilatation was excluded due to low 
availability (69%).  However, in this model, TMAO was not able to independently predict 
mortality/HF at any time point (p≥0.054). Therefore, TMAO levels showed added value to risk 
models for association with mortality outcome and mortality/HF at 1, 2 and 3 years, except for the 
extended model for mortality/HF. Associations of TMAO on outcome were not affected when 
adjusted for body mass index (BMI) on mortality and mortality/HF, except for the extended model 
of mortality/HF (Supplementary Table S3). 
When TMAO was added to the BIOSTAT-CHF compact and extended models for 
mortality at 2 years, there were only marginal gains in C-statistics (compact model with vs without 
TMAO = 0.710 vs 0.705, p=0.138; extended model with vs without TMAO = 0.728 vs 0.723, 
p=0.073) (Supplementary Table S4). However, net reclassification index (NRI) [16.8 (95%CI: 
6.6-27.1), p=0.001, 13.4 (3.0-23.9), p=0.012, respectively] and integrated discrimination 
improvement (IDI) analyses [0.5 (0.2-0.9), p=0.004, 0.5 (0.2-0.8), p=0.004, respectively] 
demonstrated the added value of TMAO (Supplementary Table S4). To note, reclassification 
analysis is known to offer greater sensitivity in highlighting improvement for the inclusion of an 
additional variable in comparison to C-statistic analysis15. 
In patients with EF<40% (n=1619), TMAO levels showed added value to BIOSTAT-CHF 
risk models for association with mortality outcome and mortality/HF at 1, 2 and 3 years, except for 
the extended model for mortality/HF at 1 year (HR≥1.27, p≤0.041, see Supplementary Table S5 
for detailed statistical results).  However, this association was not seen in patients with EF≥40%.  
BIOSTAT-CHF did not assess echocardiographic parameters beyond EF as needed for 
classification of HF phenotype (e.g. HFrEF, HFpEF), therefore effects of HF phenotype could not 
be further investigated. 
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Association of Serial Changes in TMAO Levels with Adverse Outcomes 
To understand the associations of subsequent adverse outcomes with serial changes in 
circulating TMAO levels following treatment, TMAO levels at enrolment (V1) and at the follow-
up (V2) time point at nine months after treatment were split into high and low level groups (in 
relation to median values; V1 median, 5.7 µmol/L; V2 median, 6.6 µmol/L). The groups were 
comprised of low V1 and low V2 (L/L, n=315), low V1 and high V2 (L/H, n=171), high V1 and 
low V2 (H/L, n=171), and high V1 and high V2 (H/H, n=315) levels. Analysis showed that 
patients with low TMAO levels at V1 with high levels at V2 (L/H) and those who showed high 
levels at V1 with low levels at V2 (H/L) did not show an increased association with mortality at 2 
years following the follow-up visit as compared to the reference L/L group [HR (95% confidence 
intervals); 1.13 (0.63-2.04) and 1.14 (0.64-2.03) for L/H and H/L, respectively]. However, patients 
who showed high TMAO levels at both time points (H/H) showed increased association with 
mortality at 2 years after the follow-up visit [HR 2.21 (1.43-3.43), p<0.001] (Figure 2A). Thus, 
increased association with mortality was seen in patients with sustained increases in TMAO levels 
at both enrolment and follow-up, or conversely, increased association was not seen in patients that 
exhibited low TMAO levels at either visit. 
Similar analysis was done with natriuretic peptide levels (Figure 2C). Patients were 
divided into four groups by median BNP levels for V1 and V2 (V1 median, 206 pg/mL; V2 
median, 132 pg/mL). This produced groups of 297, 148, 148, and 297 patients for L/L, L/H, H/L, 
and H/H groups, respectively. Patients who showed low BNP levels following an initially high 
level (H/L) showed a similar association with mortality (HR 1.17 (0.55-2.48), p=0.679) as 
compared to the L/L group. Patients with high levels of BNP at V2 (L/H and H/H) showed 
increased association with mortality at 2 years [L/H HR 2.70 (1.45-4.99), p=0.002; H/H HR 3.56 
(2.11-6.00), p<0.001]. Thus, natriuretic peptide showed a different trend where low natriuretic 
peptide levels after treatment at follow-up were associated with better outcomes, and high levels at 
follow-up were associated with worse outcomes regardless of initial levels.  
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To note, these associations were also seen when adjusted for renal function (Figures 2B, 
D). Changes in TMAO were associated with mortality even when adjusted for potential 
confounders such as BMI, systolic BP, EF and renal function (eGFR) (Supplementary Table S6).  
These associations were also seen when patients were divided into tertiles (high/mid/low 
TMAO levels) at V1 and V2 instead of using median levels to split into high/low groups 
(Supplementary Figure S1). Tertile analysis showed that high to high, mid to high, and high to 
mid level changes showed association with adverse outcome consistent with those of sustained 
high levels from V1 to V2 using median analysis thus confirming that sustained high levels of 
TMAO are associated with adverse outcome. 
Analysis was also done in patients with EF<40% (n=713) (supplementary Table S7). 
Association with mortality was seen in patients with sustained increases in TMAO levels at both 
V1 and V2 even after adjustment for potential confounders (BMI, systolic BP, EF and eGFR). 
 
Decision Tree Analysis 
 Decision tree analysis was done to investigate TMAO levels at V1 and V2 as risk 
stratification biomarkers for mortality at 2 years following V2 (Figure 3A). This showed that 
stratifying patients by median TMAO levels at V1 and V2 generated three groups of risk that 
confirmed associations reported by the previous Cox proportional hazards regression analysis. 
Those with TMAO levels below the median at V1 (group A) showed a similar level of risk to 
those who initially presented with high levels that subsequently showed low levels (group B); 
relative risks (RR) of groups A and B were 10.7% and 12.5%, respectively. Conversely, those who 
presented with and maintained high levels of circulating TMAO (group C) showed an increased 
level of risk (RR of 26.0%; and HR 2.10 (1.44-3.06), p<0.001 compared to group A). Kaplan-
Meier survival analysis confirmed that group C had an increased number of cumulative events 
compared to groups A and B (log-rank p<0.001, Figure 3A inset). 
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 Similar analysis was also done on natriuretic peptide levels (Figure 3B). Decision tree 
analysis showed that a high level of BNP at V2 (>132 pg/mL) was associated with worse 
prognosis irrespective of measurement levels at the initial visit. Patients who had low BNP levels 
at V2 (groups A and C) showed the lowest level of risk (RR of 6.5% and 8.0% for groups A and C, 
respectively), and those with high levels at V2 (groups B and D) showing increased levels of risk 
(group RR of 18.4% and 26.7% for groups B and D, respectively). Kaplan-Meier survival analysis 
confirmed similar levels of cumulative events for groups A and C, and increase in events for 
groups B and D (log-rank p<0.001, Figure 3B inset). These results showed effects of TMAO on 
predictive values by cut-off levels at both V1 and V2, and therefore highlighted the importance of 
serial measurements. 
 
Response of Circulating TMAO Levels to Treatment and Association with Outcomes  
 Response of TMAO levels to treatment was also investigated (Table 3) as BIOSTAT-CHF 
had also recorded dosage titrations. We hypothesized that TMAO levels would not respond to 
guideline directed medical therapy as conventional medications for treatment of HF do not target 
the gut microbiome in contrast to BNP, the comparator and reference, which is known to respond 
to treatment with lower levels16.  For patients using ACEi/ARBs, regardless of whether they had 
achieved optimal titration to recommended dosage or not, TMAO levels showed increases by V2. 
Beta-blocker use showed increases in TMAO when less than 50% optimal dosage was used but 
not when higher levels of optimization were achieved. When combined for these drugs, less than 
50% optimal titration showed increase in TMAO levels but not when higher levels of titration 
were achieved. In contrast, BNP showed reduced levels when greater than 50% optimal titration of 
either or both ACEi/ARBs and/or beta-blocker were used, but not when less than 50% optimal 
titration was achieved. TMAO levels were not responsive to optimized current guideline-based HF 
treatment in contrast to BNP levels. 
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 In patients with EF<40%, TMAO levels showed increases regardless of optimization of 
ACEi/ARBs, and those on beta-blockers did not show significant difference in patients with 
greater than 50% optimal titration but showed significant increase in those with less than 50% 
optimal titration (Supplementary Table S8). 
 Titration of ACEi/ARBs, beta-blockers or both did not show interaction with TMAO levels 
on effects on mortality (ACEi/ARBs, beta-blockers or both; Pinteraction =1.00, Pinteraction =0.242 and 
Pinteraction=0.442, respectively).  
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DISCUSSION 
 
 The present analysis of BIOSTAT-CHF validates that initial TMAO levels are associated 
with adverse outcomes (mortality and mortality/HF). In contrast to natriuretic peptides which 
responded to treatment as expected, TMAO did not respond to guideline medical treatment. 
Patients with sustained higher levels of TMAO before and after treatment were associated with 
worse outcomes, and patients with lower levels either before or after treatment did not show 
additional risk. 
 
Comparison to Previous Studies 
The present study investigated the role of the gut microbiome-derived metabolite 
biomarker of HF, TMAO, in the BIOSTAT-CHF cohort. As compared to previous acute and 
chronic HF patient cohorts in which TMAO levels have been investigated2-7, the BIOSTAT-CHF 
cohort included over 2000 patients with progressive worsening or new-onset symptoms of HF. In 
the present cohort, increased TMAO levels were independently associated with adverse outcomes 
of mortality and a composite endpoint of mortality and hospitalization due to HF. Taken together 
with past observations in acute and chronic HF cohorts2-7, elevated TMAO levels are consistently 
associated with adverse outcomes in patients with HF (mortality and/or HF rehospitalisation).  
 
Novel Findings from the Present Study 
 One of the main aims of BIOSTAT-CHF was to establish the effects of response to 
initiation and up-titration of guideline-directed medical therapy in HF patients.11 Drug therapy at 
enrolment, changes in the use of medications and up-titration to doses were recorded allowing for 
analysis of TMAO levels over time in response to and association with outcomes after treatment 
which were the first to our knowledge. Further, as natriuretic peptide levels (BNP/ NT-proBNP) 
were included in the entry criteria of BIOSTAT-CHF, comparison of temporal characteristics with 
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natriuretic peptide levels was also possible in the present study. To note, all patients in BIOSTAT-
CHF underwent treatment with furosemide ≥40mg/day or equivalent and received ≤50% of target 
doses of ACEi/ARBs and beta-blockers at time of enrolment which were then up-titrated in the 
next three months. 
 The initial finding of interest was that a low TMAO level (as compared to median) either at 
baseline or at follow-up was sufficient to confer better outcomes as compared to patients that 
showed sustained high levels at both initial and follow-up time-points. This was in contrast to 
natriuretic peptide levels, which showed only better outcomes when there were low levels at 
follow-up as consistent with previous studies which have shown that lower levels of natriuretic 
peptide with treatment are associated with favourable outcomes.16 Another finding of interest was 
that current guideline-based HF treatment did not affect TMAO levels. In fact, reduction in TMAO 
levels were not observed in patients with titration of dosages to greater than 50% of the 
recommended dosage, and a significant increase in TMAO levels was seen in patients achieving 
less than 50% optimal titration of either ACEi/ARBs or beta-blockers. In contrast, natriuretic 
peptide levels showed a decrease in response to optimal up-titration (>50%) of ACEi/ARBs and/or 
beta-blockers as consistent with previous reports that have addressed effects of HF treatment on 
natriuretic peptide levels.17,18 
On added value of TMAO levels to risk prediction, TMAO added to risk stratification of 
the BIOSTAT-CHF risk models (compact and extended) for mortality and mortality/HF at 1, 2 and 
3 years, with the exception of the extended model for mortality/HF.  
 
Clinical Implications of all the Available Evidence 
Our findings showed that current guideline-based pharmacological treatment in HF 
impacted natriuretic peptide levels as expected but did not reduce TMAO levels. Studies have 
shown that dietary modulation (e.g. vegan/vegetarian-based) as well as drugs (e.g. antibiotics, 
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small compounds) in addition to natural inhibitors (e.g. 3,3-dimethyl-1-butanol, DMB) may lower 
TMAO levels19.  
Therapeutic intervention to the gut microbiome/dysbiosis and/or intestinal permeability 
might be potential additive treatments for HF. However, TMAO lowering has yet to be shown to 
improve outcomes of heart disease and will be a topic for future investigation. 
 
Mechanistic Implications 
Although the mechanisms contributing to the increase of TMAO in the setting of HF are 
likely multifactorial, some plausible mechanisms focused on effects of intestinal dysfunction on 
increased TMAO include; 1)  increased congestion and intestinal dysfunction/congestion in HF 
leading to dysbiosis of the gut microbiome20, and 2) congestion leading to increased intestinal 
permeability21 resulting in increased entry of the precursor TMA into intestinal blood flow then 
into the circulation. 
 
Study Limitations  
BIOSTAT-CHF was an observational study, therefore optimisation and dosages were 
decided by clinical discretion.  Although there is strong evidence that high blood levels of TMAO 
correlate with cardiovascular events,2-7 there remains possibility that increased concentration of 
TMAO in patients with increased cardiovascular risk may be not a causative relationship. Other 
potential limitations are that we did not have any information regarding baseline diet, physical 
activity level and change in weight to adjust for these confounding factors. There is potential for 
residual measured and/or unmeasured confounding factors to influence association of TMAO with 
outcomes. Circulating TMAO levels likely depend on a multitude of factors including diet, gut 
microbiota composition and activity, permeability of the gut-blood barrier, activity of liver 
enzymes, rate of methylamine excretion, and effects of medications.22    
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CONCLUSION 
 
 TMAO levels were able to add to risk stratification of HF in the BIOSTAT-CHF cohort. 
Elevated levels of circulating TMAO were associated with adverse outcomes (mortality and/or HF 
hospitalisation) and added to the clinical BIOSTAT-CHF risk models. Serial analysis of TMAO 
levels with treatment showed that patients with sustained higher levels of TMAO before and after 
treatment were associated with worse outcomes, and that low levels either at baseline or at follow-
up were sufficient for association with better outcomes.   
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SUPPLEMENTARY INFORMATION 
 
 Additional Supporting Information may be found in the online version of this article: 
Table S1. Patient characteristics according to median and tertiles of TMAO at visit 1. 
Table S2. Differences in characteristics between patients with and without TMAO measurements 
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Table S3. Cox proportional hazards regression analyses for association of baseline plasma TMAO 
levels and outcomes in BIOSTAT-CHF model including BMI. 
Table S4. Reclassification analysis using continuous reclassification of adding TMAO to 
BIOSTAT-CHF compact and extended models.  
Table S5. Cox proportional hazards regression analyses for association of baseline plasma TMAO 
levels and outcomes in patients with EF<40% or EF≥40%. 
Table S6. Cox proportional hazard regression model including BMI, systolic BP, LVEF and eGFR 
for the analysis of association with TMAO changes and mortality at 2 years after visit 2.  
Table S7. Cox proportional hazard regression for the analysis of association with TMAO changes 
and mortality at 2 years after visit 2 according to EF less than or greater to 40%. 
Table S8. Response of TMAO and BNP levels to guideline-based treatment (less than 50% or not 
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Figure S1. Forest plot showing the association with outcome for patients with TMAO levels 
measured at baseline and secondary visit.  
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Table 1. Patient characteristics. 
 Total cohort 
(n=2234) 
Patients with follow-up visit (n=972) 
 Visit 1 Visit 2 p value 
TMAO (µmol/L) 5.9 [3.6-10.8] 5.7 [3.5-9.9] 6.6 [3.7-11.1] <0.001 
Demographics     
Age 70 [61-78] 69 [61-78]   
Male 1654 (74%) 727 (75%)   
Body mass index (kg/m2)  27.2 [24.2-30.8] 27.2 [24.4-30.9] 27.3 [24.3-30.9] 0.850 
Current smoker 312 (14%) 129 (13%)   
Ischemic aetiology 1214 (55%) 524 (54%)   
Hypertension 1401 (63%) 613 (63%)   
Diabetes mellitus 730 (33%) 306 (32%)   
COPD 387 (17%) 172 (18%)   
Previous HF hospitalisation 703 (32%) 292 (30%)   
NYHA class    I 52 (2%) 27 (3%) 148 (16%) 
<0.001 
                            II 768 (35%) 381 (40%) 572 (60%) 
                            III 1088 (50%) 451 (48%) 224 (24%) 
                            IV 260 (12%) 89 (9%) 11 (1%) 
LVEF (%) 30 [25-36] 30 [25-35] 35 [28-42] <0.001 
HFrEF (EF<40%) 1619 (81%) 713 (83%)   
Clinical signs     
Pulmonary congestion 1149 (52%) 463 (49%) 92 (11%) <0.001 
Peripheral oedema 1103 (59%) 372 (52%) 175 (25%) <0.001 
Systolic blood pressure (mmHg) 120 [110-139] 123 [110-140] 122 [110-140] 0.409 
Diastolic blood pressure (mmHg) 74 [66-82] 75 [67-85] 75 [65-80] 0.002 
Heart rate (beat/min) 76 [67-90] 75 [65-89] 70 [61-80] <0.001 
Medication     
  Beta-blocker 1863 (83%) 825 (85%) 906 (93%) <0.001 
  ACE inhibitor or ARB 1638 (73%) 720 (74%) 862 (89%) <0.001 
  MRA 1193 (53%) 509 (52%) 572 (59%) <0.001 
  Diuretics 2232 (100%) 971 (100%) 971 (94%) <0.001 
Laboratory      
  Haemoglobin (g/dL) 13.3 [11.9-14.5] 13.4 [12.1-14.6] 13.3 [12.0-14.3] 0.013 
  BNP (pg/mL) 231 [92-475] 206 [86-408] 132 [51-327] <0.001 
  Urea (mmol/L) 11.1 [7.4-17.9] 9.2 [6.7-14.5] 10.2 [7.0-16.0] <0.001 
  eGFR* (ml/min/1.73m2) 62 [48-79] 64 [48-81] 60 [45-78] <0.001 
  Sodium (mmol/L) 140 [137-142] 140 [137-142] 139 [137-141] 0.207 
 
Data are presented as median [interquartile range] for continuous variables or n (%) for categorical 
values. P values are quoted for Wilcoxon matched-pair signed-rank tests for continuous variables 
and McNemar tests for categorical variables. *Estimated by CKD-EPI formula. ACE=angiotensin-
converting enzyme; ARB=angiotensin receptor blocker; BNP=B-type natriuretic peptide; 
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COPD=chronic obstructive pulmonary disease; eGFR=estimated glomerular filtration rate; 
HF=heart failure; HFrEF=heart failure with reduced ejection fraction; LVEF=left ventricular 
ejection fraction; MRA=mineralocorticoid receptor antagonist; NYHA=New York Heart 
Association; TMAO=trimethylamine-N-oxide.  
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Table 2. Cox proportional hazards regression analyses for association of baseline plasma TMAO levels and outcomes in the BIOSTAT-CHF cohort.  
  
  Unadjusted 
 Adding TMAO to 
Compact model 
 Adding TMAO to 
Extended model     
  HR (95% CI) p value  HR (95% CI) p value  HR (95% CI) p value 
Mortality         
1 year 2.43 (1.93-3.05) <0.001  1.51 (1.14-2.00) 0.004  1.40 (1.03-1.89) 0.030 
2 years 2.29 (1.90-2.77) <0.001  1.49 (1.18-1.88) 0.001  1.44 (1.12-1.84) 0.004 
3 years 2.27 (1.90-2.72) <0.001  1.47 (1.18-1.84) 0.001  1.42 (1.13-1.80) 0.003 
Mortality/HF         
1 year 1.92 (1.61-2.28) <0.001  1.42 (1.06-1.90) 0.019  1.12 (0.90-1.40) 0.281 
2 years 1.91 (1.64-2.22) <0.001  1.39 (1.09-1.76) 0.007  1.19 (0.98-1.45) 0.077 
3 years 1.93 (1.66-2.23) <0.001  1.37 (1.09-1.72) 0.007  1.21 (1.00-1.46) 0.054 
 
Compact model for all-cause mortality (mortality): age, blood urea (log-transformed), BNP (log-transformed), haemoglobin and use of beta-blocker at 
baseline. Compact model for mortality or rehospitalisation due to heart failure (mortality/HF): age, previous HF hospitalisation, peripheral oedema, 
systolic blood pressure, BNP (log-transformed), haemoglobin, sodium and use of beta-blocker at baseline. Extended model for mortality: compact 
model plus ischemic aetiology, COPD, diastolic blood pressure and sodium. Extended model for mortality/HF: compact model plus current smoker, 
COPD and eGFR. Data are presented as hazard ratio (HR) and 95% confidence interval (CI). BNP=B-type natriuretic peptide; COPD=chronic 
obstructive pulmonary disease; eGFR=estimated glomerular filtration rate; HF=heart failure; TMAO=trimethylamine-N-oxide. 
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Table 3. Response of TMAO and BNP levels to guideline-based treatment (less than 50% or not of optimal recommended dosage). 
 
  TMAO (n=972)  BNP (n=890) 
Dose up-titration V1 (µmol/L) V2 (µmol/L) p value*  V1 (pg/mL) V2 (pg/mL) p value* 
ACEi/ARBs        
  <50% 6.3 [3.8-11.8] 7.1 [3.9-12.9] 0.002  237 [104-469] 172 [70-420] 0.122 
  ≥50% 5.2 [3.4-8.9] 6.2 [3.5-10.3] 0.002  171 [77-342] 108 [39-259] <0.001 
Beta-blocker        
  <50% 5.6 [3.5-9.2] 6.7 [3.7-11.2] <0.001  183 [85-392] 141 [55-369] 0.159 
  ≥50% 5.7 [3.7-10.5] 6.5 [3.7-10.8] 0.084  222 [89-434] 126 [44-277] <0.001 
Both drugs        
  Either <50% 5.7 [3.5-9.7] 6.7 [3.7-11.9] <0.001  203 [86-411] 140 [56-366] 0.053 
  Both    ≥50% 5.6 [3.6-10.1] 6.5 [3.6-10.5] 0.284  208 [88-389] 113 [37-244] <0.001 
 
p value; initial enrolment visit (V1) to the follow-up visit (V2) were compared using Wilcoxon matched-pair signed-rank test. ACEi=angiotensin-
converting enzyme inhibitor; ARB=angiotensin receptor blocker; BNP=B-type natriuretic peptide; TMAO=trimethylamine N-oxide.  
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FIGURE LEGENDS 
 
Figure 1. Cumulative incidence of events across TMAO tertiles.  
A: Cumulative incidence plot for all-cause mortality (mortality) at 3 years stratified by TMAO 
tertiles. B: Cumulative incidence plot of mortality and/or rehospitalisation due to heart failure 
(mortality/HF) at 3 years stratified by TMAO tertiles. Number of events are shown below. 
 
Figure 2. Forest plot showing the association with outcome for patients with TMAO (top) 
and BNP (bottom) levels measured at baseline and secondary visit. 
Patients were divided into four groups according to TMAO (top) and BNP (bottom) concentrations 
at the initial enrolment visit (V1) and follow-up visit (V2) relative to the median of each visit point 
(TMAO; 5.7 µmol/L and 6.6 µmol/L, BNP; 206 pg/mL and 132 pg/mL, for V1 and V2 
repsectively). H/H=high V1 and high V2; H/L=high V1 and low V2; L/H=low V1 and high V2; 
L/L=low V1 and low V2. Cox proportional hazards regression modelling was used to compare the 
risk of mortality at 2 years after V2 among the four groups of patients using L/L as the reference 
on each occasion (A and C unadjusted, B and D adjusted with renal function (eGFR at V1) for 
TMAO and BNP respectively). Data are presented as hazard ratio (HR) and 95% confidence 
interval (CI). BNP=B-type natriuretic peptide; eGFR=estimated glomerular filtration rate; 
TMAO=trimethylamine-N-oxide. 
 
Figure 3. Classification tree to show risk stratification for mortality at 2 years using 
combined measurements at baseline and secondary visit for TMAO (top) and BNP (bottom). 
A: Classification tree using plasma TMAO level at the initial enrolment visit (V1) as the initial 
classifier, followed by plasma TMAO level at follow-up visit (V2) enables effective selection of 
low- and high-risk groups of patients (main body) and increased cumulative event risk in Group C 
compared to Groups A and B (inset). B: Classification tree using plasma BNP level at V1 as the 
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initial classifier, followed by plasma BNP level at V2 enables effective selection of low- and high-
risk groups of patients (main body) and increased cumulative event risk in Groups B and D 
compared to A and C (inset). Data are presented as hazard ratio (HR) and 95% confidence interval 
(CI). Number of events are shown below. BNP=brain natriuretic peptide; TMAO=trimethylamine-
N-oxide. 
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SUPPLEMENTARY MATERIAL 
 
Table S1. Patient characteristics according to median and tertiles of TMAO at visit 1. 
  Low TMAO (<5.9) High TMAO (≥5.9) p Value 
TMAO (µmol/L) 3.6 [2.4-4.5] 10.7 [7.6-18.8] <0.001 
Demographics       
    Age 66 [58-75] 73 [65-80] <0.001 
    Male 833 (76%) 794 (72%) 0.053 
    Body mass index (kg/m2) 27.2 [24.2-31.0] 27.2 [24.2-30.4] 0.516 
    Current smoker 180 (16%) 121 (11%) <0.001 
    Ischemic aetiology 286 (26%) 434 (40%) <0.001 
    Hypertension 279 (57%) 279 (58%) 0.014 
    Diabetes mellitus  290 (26%) 440 (39%) <0.001 
    COPD 167 (15%) 220 (20%) 0.004 
    Previous HF hospitalisation  301 (27%) 391 (36%) <0.001 
    NYHA class    I 27 (3%) 24 (2%)  
                            II 427 (40%) 334 (31%)   
                            III 514 (48%) 558 (52%) <0.001 
                            IV 104 (10%) 151 (14%)   
    LVEF (%) 30 [25-35] 30 [25-38] 0.033 
    EF<40% 832 (83%) 753 (79%) 0.047 
Clinical signs       
    Pulmonary congestion 203 (28%) 284 (38%) <0.001 
    Peripheral oedema 510 (55%) 578 (64%) <0.001 
    Systolic blood pressure (mmHg) 122 [110-140] 120 [110-136] 0.017 
    Diastolic blood pressure (mmHg) 78 [70-85] 70 [65-80] <0.001 
    Heart rate (beat/min) 77 [67-90] 75 [66-88] 0.011 
Medication       
    Beta-blocker 929 (85%) 899 (82%) 0.051 
    ACE inhibitor or ARB 824 (75%) 780 (71%) 0.022 
    MRA  646 (58%) 547 (49%) <0.001 
    Diuretics  1115 (100%) 1117 (100%) 0.500 
Biochemistry       
    Haemoglobin (g/dL) 13.7 [12.4-14.7] 12.9 [11.5-14.2] <0.001 
    BNP (pg/mL) 202 [79-401] 257 [109-549] <0.001 
    Urea (mmol/L) 9.4 [6.7-15.0] 13.3 [8.9-22.1] <0.001 
    eGFR* (ml/min/1.73m2) 72 [58-87] 52 [39-67] <0.001 
    Sodium (mmol/L) 140 [137-142] 140 [137-142] 0.083 
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  Low (<4.2) Mid (4.2-8.4) High (>8.4) p Value 
TMAO (µmol/L) 2.9 [2.0-3.6] 5.9 [4.9-6.9] 15.5 [10.8-25.0] <0.001 
Demographics         
     Age 65 [58-75] 70 [62-78] 74 [65-80] <0.001 
     Male 570 (77%) 538 (72%) 546 (73%) 0.131 
     Body mass index (kg/m2) 27.2 [24.1-30.5] 27.4 [24.2-31.1] 27.1 [24.1-30.4] 0.408 
     Current smoker 122 (16%) 110 (15%) 80 (11%) 0.005 
     Ischemic aetiology 381 (53%) 410 (56%) 423 (58%) 0.135 
     Hypertension 444 (60%) 460 (62%) 497 (67%) 0.016 
     Diabetes mellitus 177 (24%) 249 (33%) 304 (41%) <0.001 
     COPD 107 (14%) 133 (18%) 147 (20%) 0.022 
     Previous HF hospitalisation 192 (26%) 231 (31%) 280 (38%) <0.001 
     NYHA class     I 22 (3%) 14 (2%) 16 (2%)  
                              II 301 (42%) 248 (35%) 219 (30%)   
                              III 331 (46%) 372 (52%) 385 (53%) <0.001 
                              IV 70 (10%) 84 (12%) 106 (15%)   
     LVEF (%) 30 [25-35] 30 [25-36] 30 [25-38] 0.217 
     EF<40% 571 (84%) 556 (82%) 492 (78%) 0.037 
Clinical signs         
     Pulmonary congestion 373 (51%) 386 (53%) 390 (54%) 0.449 
     Peripheral oedema 347 (56%) 355 (57%) 401 (66%) <0.001 
     Systolic blood pressure (mmHg) 125 [110-140] 120 [110-137] 120 [110-137] 0.003 
     Diastolic blood pressure (mmHg) 79 [70-85] 75 [68-83] 70 [63-80] <0.001 
     Heart rate (beat/min) 78 [67-90] 78 [67-90] 75 [66-87] 0.094 
Medication         
     Beta-blocker 634 (85%) 614 (82%) 625 (83%) 0.262 
     ACE inhibitor or ARB 554 (75%) 566 (76%) 518 (70%) 0.013 
     MRA  435 (59%) 391 (53%) 367 (49%) 0.001 
     Diuretics 742 (100%) 745 (100%) 745 (100%) 0.412 
Biochemistry         
     Haemoglobin (g/dL) 13.7 [12.5-14.8] 13.4 [12.1-14.6] 12.7 [11.3-14.0] <0.001 
     BNP (pg/mL) 181 [70-369] 232 [91-443] 283 [120-601] <0.001 
     Urea (mmol/L) 8.9 [6.1-13.9] 10.6 [7.4-16.6] 14.2 [9.2-23.2] <0.001 
     eGFR* (ml/min/1.73m2) 75 [61-92] 63 [51-78] 50 [35-65] <0.001 
     Sodium (mmol/L) 140 [137-142] 140 [137-142] 139 [136-141] 0.006 
Data are presented as median [interquartile range] for continuous variables or n (%) for categorical values. 
P values are quoted for Mann-Whitney U test or Kruskal-Wallis tests for continuous variables and Chi-
square tests for categorical variables. *Estimated by CKD-EPI formula. ACE=angiotensin-converting 
enzyme; ARB=angiotensin receptor blocker; BNP=B-type natriuretic peptide; COPD=chronic obstructive 
pulmonary disease; eGFR=estimated glomerular filtration rate; HF=heart failure; EF=ejection fraction; 
LV=left ventricular; MRA=mineralocorticoid receptor antagonist; NYHA=New York Heart Association; 
TMAO=trimethylamine-N-oxide.  
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Table S2. Differences in characteristics between patients with and without TMAO measurements at visit 1 and visit 2. 
 
  Visit 1   visit 2 
  
with available 
TMAO (n=2234) 
without available 
TMAO (n=282) p Value   
with available 
TMAO 
(n=972) 
without available 
TMAO (n=1262) p Value 
TMAO (µmol/L) 5.9 [3.6-10.8] -     6.6 [3.7-11.1] -   
Demographics               
  Age  70 [61-78] 71 [61-78] 0.070   69 [61-78] 71 [61-78] 0.152 
  Male  1654 (74%) 192 (68%) 0.021   727 (75%) 927 (74%) 0.253 
  Body mass index (kg/m2) 27.2 [24.2-30.8] 26.7 [23.6-30.5] 0.203  27.2 [24.3-30.9] 27.1 [24.0-30.5] 0.159 
  Current smoker  312 (14%) 41 (14%) 0.429   129 (13%) 183 (15%) 0.220 
  Ischemic aetiology  1214 (55%) 114 (51%) 0.119   524 (54%) 690 (56%) 0.201 
  Hypertension  1401 (63%) 168 (60%) 0.169   613 (63%) 788 (62%) 0.398 
  Diabetes mellitus  730 (33%) 89 (32%) 0.381   306 (32%) 424 (34%) 0.156 
  COPD  387 (17%) 49 (17%) 0.519   172 (18%) 215 (17%) 0.362 
  Previous HF hospitalisation  703 (32%) 91 (32%) 0.416   292 (30%) 411 (33%) 0.110 
  NYHA class     I 52 (2%) 4 (1%)     133 (18%) 148 (16%)   
                           II 768 (35%) 100 (36%) 
0.795 
  415 (56%) 572 (60%) 
0.331                            III 1088 (50%) 140 (50%)   189 (25%) 224 (24%) 
                           IV 260 (12%) 34 (12%)   10 (1%) 11 (1%) 
  LVEF (%) 30 [25-36] 30 [25-36] 0.959   35 [28-42] 35 [26-42] 0.173 
  EF<40%  1619 (81%) 200 (78%) 0.143   713 (83%) 906 (81%) 0.151 
Clinical signs               
  Pulmonary congestion  1149 (52%) 107 (49%) 0.402   60 (9%) 92 (11%) 0.103 
  Peripheral oedema  1103 (59%) 113 (83%) 0.172   175 (25%) 191 (24%) 0.533 
  Systolic blood pressure (mmHg) 120 [110-139] 120 [110-137] 0.212   121 [110-140] 120 [110-138] 0.236 
  Diastolic blood pressure (mmHg) 74 [66-82] 71 [65-80] 0.189   75 [65-80] 74 [67-80] 0.890 
  Heart rate (beats/min) 76 [67-90] 77 [68-90] 0.540   70 [61-80] 70 [62-80] 0.197 
Medication               
  Beta-blocker  1863 (83%) 230 (82%) 0.242   906 (93%) 1128 (89%) 0.001 
  ACE inhibitor or ARB  1638 (73%) 182 (65%) 0.001   862 (89%) 1047 (83%) <0.001 
  MRA  1193 (53%) 146 (52%) 0.325   572 (59%) 494 (60%) 0.345 
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  Diuretics  2232 (100%) 282 (100%) 0.615   971 (94%) 781 (95%) 0.416 
Biochemistry               
  Haemoglobin (g/dL) 13.3 [11.9-14.5] 13.3 [11.8-14.4] 0.858   13.3 [12.1-14.3] 13.1 [11.8-14.3] 0.084 
  BNP (pg/mL) 231 [92-475] 254 [98-510] 0.588   132 [51-327] 127 [48-331] 0.906 
  Urea (mmol/L) 11.1 [7.4-17.9] 10.4 [7.1-16.8] 0.496   10.2 [7.0-16.0] 10.7 [7.3-16.8] 0.123 
  eGFR* (ml/min/1.73m2) 62 [48-79] 61 [46-78] 0.083   60 [45-78] 55 [42-73] 0.001 
  Sodium (mmol/L) 140 [137-142] 139 [137-142] 0.430   139 [137-141] 139 [137-141] 0.160 
 
Data are presented as median [interquartile range] for continuous variables or n (%) for categorical values. P values are quoted for Mann-Whitney U tests for 
continuous variables and Chi-square tests for categorical variables. *Estimated by CKD-EPI formula. ACE=angiotensin-converting enzyme; 
ARB=angiotensin receptor blocker; BNP=B-type natriuretic peptide; COPD=chronic obstructive pulmonary disease; eGFR=estimated glomerular filtration 
rate; HF=heart failure;EF= ejection fraction; LV=left ventricular; MRA=mineralocorticoid receptor antagonist; NYHA=New York Heart Association; 
TMAO=trimethylamine-N-oxide.  
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Table S3. Cox proportional hazards regression analyses for association of baseline plasma TMAO levels and outcomes in BIOSTAT-CHF model 
including BMI. 
  Adding BMI to Compact model Adding BMI to Extended model 
  
  HR (95% CI) p value HR (95% CI) p value 
Mortality         
  1 year 1.47 (1.10–1.97) 0.010 1.38 (1.02–1.86) 0.036 
  2 years 1.46 (1.15–1.85) 0.002 1.36 (1.06–1.73) 0.014 
  3 years 1.46 (1.17–1.83) 0.001 1.36 (1.07–1.71) 0.010 
Mortality/HF         
  1 year 1.27 (1.03–1.56) 0.019 1.11 (0.89–1.40) 0.353 
  2 years 1.33 (1.11–1.59) 0.002 1.21 (1.00–1.47) 0.052 
  3 years 1.36 (1.14–1.61) 0.001 1.23 (1.02–1.48) 0.034 
 
Compact model for all-cause mortality (mortality): age, blood urea (log-transformed), BNP (log-transformed), haemoglobin and use of beta-blocker at 
baseline. Compact model for mortality or rehospitalisation due to heart failure (mortality/HF): age, previous HF hospitalisation, peripheral oedema, 
systolic blood pressure, BNP (log-transformed), haemoglobin, sodium and use of beta-blocker at baseline. Extended model for mortality: compact model 
plus ischemic aetiology, COPD, diastolic blood pressure and sodium. Extended model for mortality/HF: compact model plus current smoker, COPD and 
eGFR. Data are presented as hazard ratio (HR) and 95% confidence interval (CI). BMI=body mass index; BNP=B-type natriuretic peptide; COPD=chronic 
obstructive pulmonary disease; eGFR=estimated glomerular filtration rate; HF=heart failure; TMAO=trimethylamine-N-oxide. 
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Table S4. Reclassification analysis using continuous reclassification of adding TMAO to BIOSTAT-CHF compact and extended models. 
 
  C-statistic   
NRI [% (95% CI)] 
  
IDI [% (95% CI)] 
  
  without TMAO with TMAO p value p value p value 
Mortality at 2 years               
Compact 0.705 0.710 0.138 16.8 (6.6 - 27.1) 0.001 0.5 (0.2 - 0.9) 0.004 
Extended 0.723 0.728 0.073 13.4 (3.0 - 23.9) 0.012 0.5 (0.2 - 0.8) 0.004 
Mortality/HF at 2 years               
Compact 0.718 0.721 0.221 11.7 (2.5 - 20.8) 0.012 0.5 (0.2 - 0.8) 0.003 
Extended 0.730 0.731 0.451 6.3 (-2.9 - 15.4) 0.180 0.2 (0.0 - 0.3) 0.087 
 
Compact model for all-cause mortality (mortality): age, blood urea (log-transformed), BNP (log-transformed), haemoglobin and use of beta-blocker at 
baseline. Compact model for mortality or rehospitalisation due to heart failure (mortality/HF): age, previous HF hospitalisation, peripheral oedema, 
systolic blood pressure, BNP (log-transformed), haemoglobin, sodium and use of beta-blocker at baseline. Extended model for mortality: compact model 
plus ischemic aetiology, COPD, diastolic blood pressure and sodium. Extended model for mortality/HF: compact model plus current smoker, COPD and 
eGFR. Data are presented as net reclassification index (NRI), integrated descrimination improvement (IDI) and 95% confidence interval (CI). BNP=B-type 
natriuretic peptide; COPD=chronic obstructive pulmonary disease; eGFR=estimated glomerular filtration rate; HF=heart failure; TMAO=trimethylamine-N-
oxide. 
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Table S5. Cox proportional hazards regression analyses for association of baseline plasma TMAO levels and outcomes in patients with EF<40% 
or EF≥40%. 
 
  
Unadjusted Adding TMAO to Compact model 
Adding TMAO to 
Extended model  EF<40% (n=1619) 
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Mortality             
  1 year 2.63 (1.98–3.51) <0.001 1.69 (1.18–2.42) 0.004 1.63 (1.13–2.36) 0.009 
  2 years 2.32 (1.82–2.94) <0.001 1.51 (1.12–2.02) 0.006 1.41 (1.05–1.91) 0.024 
  3 years 2.33 (1.86–2.92) <0.001 1.53 (1.16–2.02) 0.003 1.42 (1.07–1.88) 0.016 
Mortality/HF             
  1 year 1.99 (1.60–2.47) <0.001 1.30 (1.01–1.66) 0.040 1.15 (0.88–1.51) 0.319 
  2 years 1.94 (1.61–2.34) <0.001 1.33 (1.08–1.65) 0.008 1.27 (1.01–1.60) 0.041 
  3 years 1.99 (1.66–2.39) <0.001 1.39 (1.13–1.72) 0.002 1.32 (1.05–1.65) 0.016 
 
  Unadjusted Adding TMAO to Compact model 
Adding TMAO to 
Extended model  EF≥40% (n=424) 
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Mortality             
  1 year 1.91 (1.11–3.27) 0.019 1.11 (0.59–2.08) 0.747 1.01 (0.51–1.98) 0.981 
  2 years 1.91 (1.25–2.92) 0.003 1.31 (0.81–2.12) 0.276 1.23 (0.74–2.05) 0.427 
  3 years 1.82 (1.21–2.74) 0.004 1.29 (0.81–2.05) 0.284 1.23 (0.76–2.01) 0.404 
Mortality/HF             
  1 year 1.43 (0.93–2.20) 0.106 1.08 (0.67–1.72) 0.756 0.97 (0.57–1.65) 0.900 
  2 years 1.45 (1.01–2.09) 0.044 1.17 (0.79–1.73) 0.439 1.01 (0.64–1.58) 0.980 
  3 years 1.39 (0.97–1.98) 0.073 1.12 (0.76–1.65) 0.571 0.96 (0.62–1.49) 0.844 
 
Compact model for all-cause mortality (mortality): age, blood urea (log-transformed), BNP (log-transformed), haemoglobin and use of beta-blocker at 
baseline. Compact model for mortality or rehospitalisation due to heart failure (mortality/HF): age, previous HF hospitalisation, peripheral oedema, 
systolic blood pressure, BNP (log-transformed), haemoglobin, sodium and use of beta-blocker at baseline. Extended model for mortality: compact model 
plus ischemic aetiology, COPD, diastolic blood pressure and sodium. Extended model for mortality/HF: compact model plus current smoker, COPD and 
eGFR. Data are presented as hazard ratio (HR) and 95% confidence interval (CI). BNP=B-type natriuretic peptide; COPD=chronic obstructive pulmonary 
disease; eGFR=estimated glomerular filtration rate; HF=heart failure; TMAO=trimethylamine-N-oxide. 
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Table S6. Cox proportional hazard regression model including BMI, systolic BP, LVEF and eGFR for the analysis of association with TMAO 
changes and mortality at 2 years after visit 2. 
  Unadjusted Model 1 Model 2 
 
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Mortality at 2 years             
  Low to Low 1 (reference)   1 (reference)   1 (reference)   
  Low to High 1.13 (0.63–2.04) 0.684 1.01 (0.55–1.86) 0.964 0.94 (0.41–2.15) 0.878 
  High to Low 1.14 (0.64–2.03) 0.662 0.95 (0.50–1.80) 0.875 1.22 (0.55–2.72) 0.624 
  High to High 2.21 (1.43–3.43) <0.001 1.70 (1.03–2.82) 0.039 2.34 (1.28–4.30) 0.006 
 
Patients were divided into four groups according to TMAO concentration at the initial enrolment visit (V1) and follow-up visit (V2) relative to the median of 
each visit point (TMAO; 5.7 µmol/L and 6.6 µmol/L for V1 and V2 respectively). Cox proportional hazards regression modelling was used to compare the 
risk of mortality at 2 years after V2 among the four groups of patients using Low to Low as the reference on each. Data are presented as hazard ratio (HR) and 
95% confidence interval (CI).  
Model 1 = adjusted for BMI, systolic BP, LVEF and eGFR (at Visit 1),  
Model 2 = adjusted for changes of BMI, systolic BP, LVEF and eGFR (absolute changes from V1 to V2).  
BMI=body mass index; BP=blood pressure; eGFR=estimated glomerular filtration rate; LV=left ventricular; TMAO=trimethylamine-N-oxide. 
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Table S7. Cox proportional hazard regression models for the analysis of association with TMAO changes and mortality at 2 years after visit 2 according to 
EF less than or greater to 40%.  
 Unadjusted model 1 model 2 
 EF<40% (n=713) 
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Mortality at 2 years             
  Low to Low 1 (reference)   1 (reference)   1 (reference)   
  Low to High 1.04 (0.48–2.26) 0.916 0.91 (0.41–2.03) 0.816 0.80 (0.28–2.28) 0.674 
  High to Low 1.25 (0.61–2.56) 0.535 1.16 (0.56–2.34) 0.875 1.49 (0.62–3.61) 0.377 
  High to High 2.27 (1.30–3.94) <0.001 1.99 (1.08–3.64) 0.026 2.62 (1.31–5.22) 0.006 
 
  Unadjusted model 1 model 2 
 EF≥40% (n=151) 
  HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Mortality at 2 years             
  Low to Low 1 (reference)   1 (reference)   1 (reference)   
  Low to High 1.16 (0.38–3.54) 0.800 1.30 (0.42–4.09) 0.650 2.36 (0.21–27.0) 0.489 
  High to Low 0.92 (0.28–3.07) 0.897 1.10 (0.32–3.90) 0.871 3.79 (0.32–44.7) 0.290 
  High to High 1.74 (0.75–4.08) 0.200 1.87 (0.68–5.11) 0.225 6.75 (0.79–57.8) 0.081 
 
Patients were divided into four groups according to TMAO concentration at the initial enrolment visit (V1) and follow-up visit (V2) relative to the median of 
each visit point (EF<40%; 5.2 µmol/L and 6.2 µmol/L for V1 and V2, EF>40%; 5.9 µmol/L and 8.1 µmol/L for V1 and V2, respectively). Cox proportional 
hazards regression modelling was used to compare the risk of mortality at 2 years after V2 among the four groups of patients using Low to Low as the 
reference on each. Data are presented as hazard ratio (HR) and 95% confidence interval (CI).  
Model 1 = adjusted for BMI, systolic BP, LVEF and eGFR (at Visit 1),  
Model 2 = adjusted for changes of BMI, systolic BP, LVEF and eGFR (absolute changes from V1 to V2).  
BMI=body mass index; BP=blood pressure; eGFR=estimated glomerular filtration rate; LV=left ventricular; TMAO=trimethylamine-N-oxide. 
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Table S8. Response of TMAO and BNP levels to guideline-based treatment (less than 50% or not of optimal recommended dosage) according to EF less than 
or greater to 40%.  
 
 EF<40% (n=713) TMAO (n=713)     BNP (n=660)   
     Dose up-titration  V1 (µmol/L) V2 (µmol/L) p value   V1 (pg/mL) V2 (pg/mL) p value 
ACEi/ARBs               
  <50%  5.7 [3.6-10.1] 6.8 [3.6-11.1] 0.018   237 [106–453] 180 [73–410] 0.200 
  ≥50%  4.9 [3.2-8.5] 6.0 [3.4-9.5] 0.018   176 [81–348] 106 [38–262] <0.001 
Beta-blocker               
  <50%  5.1 [3.2-8.7] 6.4 [3.5-10.5] <0.001   183 [85–385] 146 [56–380] 0.486 
  ≥50%  5.5 [3.5-9.2] 6.0 [3.5-9.9] 0.404   225 [102–434] 127 [42–267] <0.001 
Both drugs                
  Either <50% 5.1 [3.5-8.9] 6.3 [3.5-10.3] <0.001   201 [89–402] 141 [56–361] 0.098 
  Both ≥50%  5.6 [3.5-9.1] 6.1 [3.4-9.7] 0.630   224 [97–425] 114 [37–250] <0.001 
 
EF≥40% (n=151) TMAO (n=151)     BNP (n=142)   
     Dose up-titration  V1 (µmol/L) V2 (µmol/L) p value   V1 (pg/mL) V2 (pg/mL) p value 
ACEi/ARBs               
  <50%  6.7 [3.6-11.7] 9.8 [5.2-20.2] 0.002   236 [89–368] 193 [73–483] 0.104 
  ≥50%  5.5 [3.8-8.7] 7.1 [3.3-11.8] 0.119   137 [49–251] 102 [42–198] 0.437 
Beta-blocker               
  <50%  6.0 [3.3-8.9] 8.0 [4.6-13.3] 0.026   182 [66–341] 152 [51–417] 0.763 
  ≥50%  6.1 [4.1-11.7] 8.3 [4.9-14.9] 0.015   151 [68–283] 126 [55–236] 0.613 
Both drugs                
  Either <50% 6.3 [3.4-9.6] 8.2 [4.8-14.6] 0.001   186 [69–346] 153 [57–443] 0.120 
  Both ≥50%  5.2 [4.1-10.8] 7.9 [4.3-12.7] 0.357   140 [56–250] 94 [46–190] 0.101 
 
p value; initial enrolment visit (V1) to the follow-up visit (V2) were compared using Wilcoxon matched-pair signed-rank test. ACEi=angiotensin-converting 
enzyme inhibitor; ARB=angiotensin receptor blocker; BNP=B-type natriuretic peptide; TMAO=trimethylamine N-oxide.   
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     Figure S1. Forest plot showing the association with outcome for patients with TMAO levels measured at baseline and secondary visit. 
Patients were divided into nine groups according to TMAO concentrations at the initial enrolment visit (V1) and follow-up visit (V2) relative to the tertile of 
each visit point (tertile 1 (low); <4.1 µmol/L and <4.6 µmol/L, tertile 2 (mid); 4.1－8.0 µmol/L and 4.6－9.1 µmol/L, tertile 3 (high); >8.0 µmol/L and >9.1 
µmol/L for V1 and V2 respectively). Cox proportional hazards regression analysis was used to compare the risk of mortality at 2 years after V2 among the 
nine groups of patients using Low to Low as the reference. Data are presented as hazard ratio (HR) and 95% confidence interval (CI). 
TMAO=trimethylamine-N-oxide. 
 
